

08 August 2022

Researching the incidence and treatment of oesophageal and gastric cancer.

Information as available from RISOH (Regional information system Oncology / Haematology):

Please Note: Stage - Advanced/Metastatic not in guery field so manual check of patients treated April June 2022 with Gastric or Oesophageal regimen

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin): <5
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin): <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine): <5
- Any other systemic anti-cancer therapy

Cispl/Etop(Gastric): <5 CX 60/625 (Gastric): 5 Docetaxel (Gastric): <5 FLOT (Gastric): 12 OX 80/375 (OG): <5

OX 80/375 Trast (OG): <5 Docetaxel (oesoph): <5 GemCarb (Pall Oeso): <5 Nivo480mg MSI-H Oesp: <5

• Palliative care only: not available via RISOH

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine): 7
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine): 51
- Nivolumab monotherapy : <5
- Nivolumab and Ipilimumab : <5
- Any other systemic anti-cancer therapy

CispEtop (Oeso): <5 Doxetaxel (Oesoph): <5 EtopCarbAUC5(PalOes): <5 GemCarb(Pall Oeso): <5 IMDG (Pall Oeso): <5 Wkly Carb XRT (oeso): <5

Wkly Pac/CarbXRT Oes: <5

Palliative care only: not available via RISOH



08 August 2022

Q3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- Oesophageal adenocarcinoma: <5
- Oesophageal squamous cell carcinoma: <5

Q4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine): 7
- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine): 28
- Nivolumab monotherapy : <5
- Nivolumab and Ipilimumab : <5
- Any other systemic anti-cancer therapy

Doxetaxel (Oesoph): <5 EtopCarbAUC5(PalOes): <5 GemCarb(Pall Oeso): <5 IMDG (Pall Oeso): <5

• Palliative care only: not available via RISOH

Contact: publicliaison@belfasttrust.hscni.net